Pacific Biosciences of California Inc. Common Stock (PACB)
Stock · NASDAQ · Industrials
$1.74as of 10/16/2026
Price chart
Active signals
PACB Signal Track Record
How signals performed across all stocks →What PACB's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 30 | -1.5% | 47% | September 17, 2026 |
| Bollinger Band Breakout | 26 | -7.5% | 31% | September 24, 2026 |
| Bollinger Band Breakdown | 18 | -1.2% | 44% | August 6, 2026 |
| 200-Day Moving Average TouchActive now | 8 | -21.7% | 13% | September 24, 2026 |
| Any 20-session window (baseline) | -1.8% | 47% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About PACB
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solutions to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-read sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library forma…
- Sector
- Industrials
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Employees
- 485
- Website
- www.pacb.com/
Fundamentals
- 1-day range
- $1.74$1.96
- Market cap
- $361.85M
- P/E (trailing)
- —
- P/E (forward)
- -4.16
- EPS (trailing)
- $-0.43
- Dividend yield
- —
- Beta
- 2.25
- Avg. volume
- 10.95M
How Pacific Biosciences of California Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 25, 2026 · via SEC EDGAR / Finnhub
Forecasts
7 analyst ratings
Pacific Biosciences of California Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- PACBPacific Biosciences of California Inc. Common Stock$1.73▼ 11.73%Market cap $361.85MP/E —$1.07$3.44
- LABStandard BioTools Inc. Common Stock$0.63▼ 4.55%Market cap $313.21MP/E 2.92$0.6251$1.72
- CTKBCytek Biosciences Inc. Common Stock$5.25▼ 2.96%Market cap $537.23MP/E —$3.31$6.21
- QTRXQuanterix Corporation Common Stock$2.87▼ 6.51%Market cap $180.42MP/E —$2.15$8.77
- SEERSeer Inc. Class A Common Stock$2.03▼ 0.49%Market cap $120.41MP/E —$1.55$2.41
- NAUTNautilus Biotechnology Inc. Common Stock$2.06▼ 4.63%Market cap $112.76MP/E —$0.8399$4.31
- RPIDRapid Micro Biosystems Inc. Class A Common Stock$0.764▼ 9.59%Market cap $96.03MP/E —$0.8087$4.94
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| PACB Pacific Biosciences of California Inc. Common Stock | $361.85M | — | $1.73 | ▼ 11.73% | $1.07$3.44 |
| LAB Standard BioTools Inc. Common Stock | $313.21M | 2.92 | $0.63 | ▼ 4.55% | $0.6251$1.72 |
| CTKB Cytek Biosciences Inc. Common Stock | $537.23M | — | $5.25 | ▼ 2.96% | $3.31$6.21 |
| QTRX Quanterix Corporation Common Stock | $180.42M | — | $2.87 | ▼ 6.51% | $2.15$8.77 |
| SEER Seer Inc. Class A Common Stock | $120.41M | — | $2.03 | ▼ 0.49% | $1.55$2.41 |
| NAUT Nautilus Biotechnology Inc. Common Stock | $112.76M | — | $2.06 | ▼ 4.63% | $0.8399$4.31 |
| RPID Rapid Micro Biosystems Inc. Class A Common Stock | $96.03M | — | $0.764 | ▼ 9.59% | $0.8087$4.94 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- PacBio (PACB) Stock Gets Fair Value Boost After UBS Starts Coverage NeutralYahoo · 10/9/2026
- Why Pacific Biosciences of California (PACB) Dipped More Than Broader Market TodayYahoo · 10/8/2026
- PacBio Sinks 8% as TychoBio Endorses Its “Highest Quality Biological Data” – the Real Story Is More ComplicatedYahoo · 10/6/2026
- PacBio, TychoBio Collaborate Over Generation Of RNA Data To Train Models For RNA Therapy Designbenzinga · 10/6/2026
- PacBio and TychoBio Collaborate to Train AI Models for Rare Disease RNA TherapeuticsYahoo · 10/6/2026
- Apogee Enterprises Posts Upbeat Q2 Earnings, Joins Constellation Energy, Freshworks And Other Big Stocks Moving Higher On TuesdayBenzinga · 10/6/2026
- PacBio, TychoBio Collaborate Over Generation Of RNA Data To Train Models For RNA Therapy DesignBenzinga · 10/6/2026
- Why PacBio (PACB) Stock Is Trading Up TodayYahoo · 10/6/2026
- PepsiCo, Delta Lead Upcoming Earnings Slate; Fed Minutes In FocusSeekingAlpha · 10/3/2026
Insider Activity
Insider Actions →- Gibson James R II · October 6, 2026 · Option Exercise500.0K @ $1.18
- Gibson James R II · October 6, 2026 · Sale661.8K @ $3.11
- Van Oene Mark · August 17, 2026 · Sale26.9K @ $1.13
- Van Oene Mark · August 10, 2026 · Grant489.1K
- Van Oene Mark · August 10, 2026 · Grant1.97M
- LIVINGSTON RANDALL S · June 3, 2026 · Grant223.5K
- ORDONEZ KATHY · June 3, 2026 · Grant223.5K
- MILLIGAN JOHN F · June 3, 2026 · Grant223.5K
- Christopher Gibson · June 3, 2026 · Grant74.5K
- Smith Christopher M · June 3, 2026 · Grant223.5K
- Hannah Valantine · June 3, 2026 · Grant223.5K
- Ericson William W. · June 3, 2026 · Grant223.5K
- Marshall Mohr · June 3, 2026 · Grant223.5K
Institutional Ownership
March 31, 2026
- Total shares held
- 184.28M
- Total value held
- $240.66M
- Institutional holders
- 225
- Unknown36.27M
- Unknown25.27M
- Unknown20.45M
- Unknown12.78M
- Unknown7.04M
- Unknown7.04M
- Unknown6.98M
- Unknown6.12M
- Unknown4.89M
- Unknown3.64M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
PACB Pushes HiFi Sequencing for Clinical Growth
Pacific Biosciences is focusing on its HiFi sequencing technology to drive clinical adoption and achieve $40 million in savings. This strategic push aims to address the company's ongoing profitability challenges while targeting long-term growth. The stock recently saw a volume spike and touched its 200-day moving average, reflecting heightened market interest in these operational updates.
PACB Pushes HiFi Sequencing for Clinical Growth. Pacific Biosciences is focusing on its HiFi sequencing technology to drive clinical adoption and achieve $40 million in savings. This strategic push aims to address the company's ongoing profitability challenges while targeting long-term growth. The stock recently saw a volume spike and touched its 200-day moving average, reflecting heightened market interest in these operational updates.